Northern Trust Corp Buys 32,875 Shares of Seres Therapeutics Inc (MCRB)

Northern Trust Corp lifted its stake in Seres Therapeutics Inc (NASDAQ:MCRB) by 16.2% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 235,766 shares of the biotechnology company’s stock after purchasing an additional 32,875 shares during the quarter. Northern Trust Corp owned about 0.58% of Seres Therapeutics worth $2,664,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the company. Parametric Portfolio Associates LLC boosted its holdings in Seres Therapeutics by 1.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 21,335 shares of the biotechnology company’s stock valued at $240,000 after acquiring an additional 279 shares during the period. American International Group Inc. boosted its holdings in Seres Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 727 shares during the period. TIAA CREF Investment Management LLC boosted its holdings in Seres Therapeutics by 14.4% during the 1st quarter. TIAA CREF Investment Management LLC now owns 110,076 shares of the biotechnology company’s stock valued at $1,241,000 after acquiring an additional 13,825 shares during the period. Vanguard Group Inc. boosted its holdings in Seres Therapeutics by 7.1% during the 1st quarter. Vanguard Group Inc. now owns 1,565,663 shares of the biotechnology company’s stock valued at $17,645,000 after acquiring an additional 103,456 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Seres Therapeutics by 5.8% in the 1st quarter. Geode Capital Management LLC now owns 166,325 shares of the biotechnology company’s stock worth $1,874,000 after buying an additional 9,060 shares during the period. Hedge funds and other institutional investors own 77.83% of the company’s stock.

Seres Therapeutics Inc (MCRB) opened at $9.87 on Wednesday. Seres Therapeutics Inc has a 1 year low of $8.85 and a 1 year high of $17.42. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.53 and a quick ratio of 6.53.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.22. The company had revenue of $23.00 million for the quarter, compared to analyst estimates of $17.29 million. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. The firm’s quarterly revenue was up 76.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.46) EPS. equities research analysts anticipate that Seres Therapeutics Inc will post -2.33 earnings per share for the current year.

Several equities research analysts have weighed in on the company. Zacks Investment Research upgraded Seres Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Tuesday. BidaskClub cut Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Cowen reiterated a “buy” rating on shares of Seres Therapeutics in a report on Monday, October 2nd. CIBC initiated coverage on Seres Therapeutics in a research report on Friday, October 13th. They issued an “outperform” rating and a $19.00 price target for the company. Finally, Oppenheimer initiated coverage on Seres Therapeutics in a research report on Thursday, October 12th. They issued an “outperform” rating and a $19.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. Seres Therapeutics has an average rating of “Buy” and an average target price of $18.00.

ILLEGAL ACTIVITY NOTICE: “Northern Trust Corp Buys 32,875 Shares of Seres Therapeutics Inc (MCRB)” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://ledgergazette.com/2017/12/06/seres-therapeutics-inc-mcrb-shares-bought-by-northern-trust-corp.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply